CDR-Life revealed the FDA's approval for clinical trial application for their drug, CDR404, aimed at addressing solid tumor conditions.

Doxycycline is a tetracyclin-like broad-spectrum antibiotic that stops bacteria from growing and replicating by inhibiting the synthesis of bacterial proteins.

Omeprazole, a common PPI, is used to treat gastrointestinal conditions like GERD, peptic ulcers, and Zollinger-Ellison syndrome.

Long-term results show Opdivo combined with Yervoy outlasts Sunitinib in survival outcomes for advanced or metastatic kidney cancer patients who haven't received prior treatment over an 8-year period.

Lisinopril is an ACE inhibitor often prescribed for hypertension, heart failure, and other heart conditions.

Vanda Pharmaceuticals Granted Green Light by FDA to Advance with Experimental Antisense Oligonucleotide Therapy, VCA-894A, for Managing Charcot-Marie-Tooth Disease, Subtype 2S.

Hydroxyzine is a first-generation antihistamine that is commonly used for the treatment of various allergic conditions such as hives and itching.

Fentanyl, a tiny molecule drug, is a COX-2 inhibitor that specifically targets the COX-2 enzyme causing inflammation and pain.

Opdivo® (nivolumab) and CABOMETYX® (cabozantinib) Show Long-Term Survival in 4-Year CheckMate-9ER Trial for 1st-Line Advanced RCC.

Meloxicam, a small molecule drug, is a COX-2 inhibitor that targets the enzyme causing inflammation and pain.

Scholar Rock Reveals U.S. FDA Approval for Phase 2 Trial Commencement, Testing Apitegromab for Obesity Management.

Cyclobenzaprine is a drug opposing ADRA2, 5-HT2A, and H1 receptors, approved to treat muscle spasticity, fibromyalgia, stress disorders, back pain, and both active and post-COVID-19 symptoms.